May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Moxifloxacin Combined With Bevacizumab (Avastin®) for Macular Edema Secondary to Branch and Central Retinal Vein Occlusions
Author Affiliations & Notes
  • J. S. Bryan
    Retina Institute of Hawaii, Honolulu, Hawaii
  • M. D. Bennett
    Retina Institute of Hawaii, Honolulu, Hawaii
  • C. S. Otto
    Retina Institute of Hawaii, Honolulu, Hawaii
  • H. A. Williams
    Retina Institute of Hawaii, Honolulu, Hawaii
  • Footnotes
    Commercial Relationships  J.S. Bryan, None; M.D. Bennett, None; C.S. Otto, None; H.A. Williams, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2687. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. S. Bryan, M. D. Bennett, C. S. Otto, H. A. Williams; Intravitreal Moxifloxacin Combined With Bevacizumab (Avastin®) for Macular Edema Secondary to Branch and Central Retinal Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2687. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate whether intravitreal Moxifloxacin combined with Avastin might have a positive biologic effect in the treatment of Macular edema associated with branch and central retinal vein occlusions (BRVO and CRVO).

Methods: : Seventeen BRVO patients and eleven CRVO patients with macular edema were enrolled. Patients received the moxifloxacin/Avastin intravitreal combination at 6 weekly intervals at the discretion of the investigator. The primary endpoint is the incidence and severity of adverse events. Secondary endpoints include changes in the following measures from baseline to months 6 and 12: best-corrected ETDRS visual acuity, central retinal thickness and macular edema as assessed by optical coherence tomography (OCT), and extent of edema as assessed by fluorescein angiography (FA).

Results: : To date, the patients enrolled in this study have demonstrated no adverse events. Preliminary visual results demonstrated an average acuity improvement of 23.2 letters in the BRVO group and 19.4 letters in the CRVO group. Dosing varied from one to six intravitreal injections. OCT and FA both demonstrated a reduction in edema. Twelve-month data will be presented.

Clinical Trial: : www.clinicaltrials.gov NCT00464581

Keywords: edema • vascular occlusion/vascular occlusive disease • ischemia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×